NCT06082986View on ClinicalTrials.gov

A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

June 5, 2024

Study Completion Date

June 5, 2024

Conditions
Crohn Disease
Interventions
DRUG

Ustekinumab

No interventions will be administered as a part of this study. Participants received ustekinumab as per their routine clinical practice.

Trial Locations (3)

310000

Sir Run Run Shaw Hospital, affiliated with Zhejiang University, School of Medicine, Hangzhou

510000

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

NCT06082986 - A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China | Biotech Hunter | Biotech Hunter